Company profilePharmaceutical#1078 of 1,318 in Pakistan✓ No DRAP alerts

Atco Laboratories Ltd DSL: 025

Pharmaceutical company · 2 brands · 4 molecules

Ranked #37 of 44 companies in Antineoplastics

2 registered products 4 pharmaceutical brands 4 distinct molecules 0 DRAP alerts

Company overview

2
registered products
4
pharmaceutical brands
4
distinct molecules
1
therapeutic classes
0
DRAP alerts

Atco Laboratories Ltd DSL: 025 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 2 product registrations across 4 distinct molecules. Its portfolio is concentrated in Antineoplastics. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Atco

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20261

Top molecules by brand count

Paclitaxel ...... 6 Mg1 brand
Paclitaxelusp........6Mg1 brand
Paclitaxel1 brand
Desmopressin ...... 0.1 Mg1 brand

Therapeutic classes

Antineoplastics · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official6 products · Rs 6,122.53 – Rs 41,977.31
Median across source: Rs 21,892.22

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

AJ Mirza Pharma Pvt Ltd DSL: 235 holds 18 molecules not in this portfolio
AtorvastatinBovine Lipid Extract SurfactantCapecitabineEntecavirErlotinibFlutamide
NOVARTIS PHARMA (PAK) LTD holds 3 molecules not in this portfolio
LevocetirizineOctreotidePaclitaxel
Merixil Pharma DSL: DHO-ISB-1745 holds 11 molecules not in this portfolio
BendamustineCapecitabineDocetaxelFilgrastimFilgrastim (Recombinant Human Granulocyte Colony-Stimulating Factor InjectionLeuprorelin

Get the full profile for Atco

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.